日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

奥洛珠单抗联合甲氨蝶呤:106周治疗的安全性和有效性

Feist, Eugen; Fleischmann, Roy M; Fatenejad, Saeed; Bukhanova, Daria; Grishin, Sergey; Kuzkina, Sofia; Luggen, Michael; Nasonov, Evgeniy; Samsonov, Mikhail; Smolen, Josef S

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

Olokizumab(一种抗白细胞介素 6 的单克隆抗体)联合甲氨蝶呤治疗甲氨蝶呤控制不佳的类风湿性关节炎患者:一项随机对照 III 期研究的疗效和安全性结果

Nasonov, Evgeniy; Fatenejad, Saeed; Feist, Eugen; Ivanova, Mariana; Korneva, Elena; Krechikova, Diana G; Maslyanskiy, Aleksey L; Samsonov, Mikhail; Stoilov, Rumen; Zonova, Elena V; Genovese, Mark

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Olokizumab(一种抗白细胞介素-6的单克隆抗体)联合甲氨蝶呤治疗肿瘤坏死因子抑制剂治疗控制不佳的类风湿性关节炎患者:一项随机对照III期研究的疗效和安全性结果

Feist, Eugen; Fatenejad, Saeed; Grishin, Sergey; Korneva, Elena; Luggen, Michael E; Nasonov, Evgeniy; Samsonov, Mikhail; Smolen, Josef S; Fleischmann, Roy M

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study

一项为期2年的双盲随机研究比较了依那西普联合柳氮磺胺吡啶与单用依那西普治疗类风湿性关节炎患者的疗效、安全性和患者报告结局。

Combe, B; Codreanu, C; Fiocco, U; Gaubitz, M; Geusens, P P; Kvien, T K; Pavelka, K; Sambrook, P N; Smolen, J S; Khandker, R; Singh, A; Wajdula, J; Fatenejad, S

Subtle changes in individual joints result in both positive and negative change scores in a patient: results from a clinical trial in patients with rheumatoid arthritis

单个关节的细微变化会导致患者评分出现正负变化:一项针对类风湿性关节炎患者的临床试验结果

Lukas, C; Landewé, R; Fatenejad, S; van der Heijde, D

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial

放射学损伤程度和放射学进展是身体功能的决定因素:TEMPO试验的纵向分析

van der Heijde, D; Landewé, R; van Vollenhoven, R; Fatenejad, S; Klareskog, L

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

TEMPO试验中依那西普联合甲氨蝶呤治疗类风湿性关节炎的患者报告结局

van der Heijde, D; Klareskog, L; Singh, A; Tornero, J; Melo-Gomes, J; Codreanu, C; Pedersen, R; Freundlich, B; Fatenejad, S

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

依那西普和柳氮磺胺吡啶单药及联合用药治疗虽已接受柳氮磺胺吡啶治疗但仍处于活动期的类风湿关节炎患者:一项双盲对照研究

Combe, B; Codreanu, C; Fiocco, U; Gaubitz, M; Geusens, P P; Kvien, T K; Pavelka, K; Sambrook, P N; Smolen, J S; Wajdula, J; Fatenejad, S

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis

对于强直性脊柱炎患者,每周一次 50 毫克依那西普与每周两次 25 毫克依那西普疗效相当。

van der Heijde, D; Da Silva, J C; Dougados, M; Geher, P; van der Horst-Bruinsma, I; Juanola, X; Olivieri, I; Raeman, F; Settas, L; Sieper, J; Szechinski, J; Walker, D; Boussuge, M-P; Wajdula, J S; Paolozzi, L; Fatenejad, S

Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results

不同缓解和持续缓解分类定义的比较:1 年 TEMPO 结果

van der Heijde, D; Klareskog, L; Boers, M; Landewé, R; Codreanu, C; Bolosiu, H D; Pedersen, R; Fatenejad, S